Patrick Daly

DocwireNews

Azacitidine and nivolumab (aza-nivo) improved response in treatment-naive myelodysplastic syndromes (MDS) and showed superior overall survival (OS) in intermediate-risk disease compared with azacitidine and ipilimumab (aza-ipi), according to a study presented at the 66th American Society of Hematology Annual Meeting &amp; Exposition.
The triplet combination of azacitidine, ipilimumab, and nivolumab (aza-ipi-nivo) did not significantly improve outcomes and increased toxicity and posttransplant mortality, said presenting author, Ian Bouligny, MD, of the University of Texas MD Anderson Cancer Center.
The analysis included 66 patients aged 18 years and older (median age, 68 years; range, 39–86) who received aza-ipi (n=33), aza-nivo (n=20), or aza-ipi-nivo (n=13).
Among the participants, the majority were transfusion dependent (76%); the most common driver mutation was TP53 (46%; P=.003); the median International Prognostic Scoring System-Molecular (IPSS-M) score was 1.59 (range, –1.55 to 4.08); and a significant proportion of patients had  very poor-risk disease (47%; P=.042) according to the revised IPSS.
The study reported the following overall response rate (ORR; complete response [CR], CR with limited count recovery [CRl], or hematologic improvement), composite CR rate (CRc; CR or CRl), and median OS for each treatment group.
<table width="100%">
<tbody>
<tr>
<td width="25%">Treatment</td>
<td width="25%">ORR</td>
<td width="25%">CRc</td>
<td width="25%">Median OS (P=.666)</td>
</tr>
<tr>
<td width="25%">Aza-ipi</td>
<td width="25%">27%</td>
<td width="25%">13.3%</td>
<td width="25%">22.7 months</td>
</tr>
<tr>
<td width="25%">Aza-nivo</td>
<td width="25%">55%</td>
<td width="25%">40%</td>
<td width="25%">14.3 months</td>
</tr>
<tr>
<td width="25%">Aza-ipi-nivo</td>
<td width="25%">54%</td>
<td width="25%">46%</td>
<td width="25%">11.8 months</td>
</tr>
</tbody>
</table>
The ORR did not differ significantly between groups, whereas the CR rate was significantly improved with aza-nivo compared with aza-ipi (40% vs 7%; P=.009).
In what authors described as a “landmark analysis,” aza-nivo was associated with superior OS compared with aza-ipi among patients with IPSS-R intermediate-risk MDS (not reached vs 25.6 months, P=.049).
Secondary analyses suggested IPSS-R intermediate-risk was associated with significantly improved survival compared with high- or very high-risk (77.7 months vs 10.9 months; P&lt;.001), and ava-ipi-nivo was associated with inferior OS after transplant compared with the doublet regimens (13.7 months vs 49.6 months; P=.008).
“Here, we present the mature data of three immunotherapy-based hypomethylating agent combinations&#8230;aza-nivo was associated with improved CR and—for IPSS-R intermediate-risk MDS—OS compared to aza-ipi,” Dr. Bouligny and colleagues summarized.
Reference
Bouligny IM, Montalban-Bravo G, Sasaki K, et al. A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndromes. Abstract #4601. Presented at the 66th American Society of Hematology Annual Meeting &amp; Exposition; December 7-10, 2024; San Diego, California.

Comparing Azacitidine, Immune Checkpoint Inhibitor Regimens in MDS

ASH 2024

Cecilia Brown

What Patients With NSCLC Say About Treatment-Related Toxicities, Therapeutic Drug Monitoring

Non-Small Cell Lung Cancer

Samuel Cytryn, MD

Impact of Zolbetuximab on Gastric Cancer Treatment

Gastric Cancer

Latest News

Azacitidine plus nivolumab especially demonstrated favorable efficacy compared to other combinations.

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe